Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus
| Autor: | Sanjay Patel, J. Troost, Guntram Schernthaner, Anthony H. Barnett, M. von Eynatten, Hans-Juergen Woerle, Angela Emser |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Blood Glucose
Male medicine.medical_specialty Endocrinology Diabetes and Metabolism Population Linagliptin Type 2 diabetes Pharmacology Placebo Gastroenterology Endocrinology Internal medicine Internal Medicine Humans Hypoglycemic Agents Medicine education Adverse effect Randomized Controlled Trials as Topic Dipeptidyl-Peptidase IV Inhibitors education.field_of_study Dose-Response Relationship Drug business.industry Incidence (epidemiology) Middle Aged medicine.disease Sulfonylurea Compounds Clinical Trials Phase III as Topic Diabetes Mellitus Type 2 Tolerability Purines Concomitant Quinazolines Female business medicine.drug |
| Zdroj: | Diabetes, Obesity and Metabolism. 14:470-478 |
| ISSN: | 1462-8902 |
| DOI: | 10.1111/j.1463-1326.2012.01565.x |
| Popis: | AIMS To assess the safety and tolerability of the dipeptidyl peptidase-4 inhibitor linagliptin in patients with type 2 diabetes. METHODS Data were pooled from eight randomized, double-blind, placebo-controlled Phase III clinical trials lasting ≤24 weeks. Incidences were calculated with descriptive statistics for the overall population and for subgroups of elderly and renally impaired patients. RESULTS A total of 2523 patients received linagliptin 5 mg once daily and 1049 patients received placebo. The overall incidence of adverse events (AEs) or serious AEs with linagliptin was similar to placebo (AEs 55.8% vs. 55.0%; serious AEs 2.8% vs. 2.7%). Overall aggregated infection incidence was 19.5% for linagliptin and 21.4% for placebo. Similar or reduced incidence of AEs versus placebo were seen with linagliptin for upper respiratory tract infection (3.3% vs. 4.9%), headache (2.9% vs. 3.1%), urinary tract infection (2.2% vs. 2.7%), blood and lymphatic disorders (1.0% vs. 1.2%), hypersensitivity (0.1% vs. 0.1%), hepatic enzyme increase (0.1% and 0.1%) and serum creatinine increase (0.0% and 0.1%). There was a slight increased frequency of nasopharyngitis (5.9% vs. 5.1%) and cough (1.7% vs. 1.0%) with linagliptin. Hypoglycaemia incidence was 8.2% for linagliptin and 5.1% for placebo; incidence was higher in patients with a background of sulphonylurea therapy (20.7% and 13.3%, respectively). In patients not receiving concomitant sulphonylurea, the hypoglycaemic incidence with linagliptin was very low in both the total population ( |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text